You are here

  • Home
  • Archive
  • Volume 81, Issue 7
  • Correction: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
Free

http://dx.doi.org/10.1136/annrheumdis-2021-220647corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 2021;80:1330–1338. doi: 10.1136/annrheumdis-2021-220647

    The correct spelling of the author’s name is Dr Tal Gazitt.

    Linked Articles